Skip to main content

Powered by curiosity. Inspired by people.

We want to do more for people living with neurodegenerative diseases and their families. We want to partner with individuals and companies who share our passion for bringing innovative ideas and solutions to the neurodegenerative disease community. In working together, we can leverage our strengths, assets and relationships to make an impact on the lives of those who need it most.

Partner with Amylyx

True collaboration is the fastest way forward. If you are a researcher or biotech company looking for a partner in your mission to improve the lives of those living with neurodegenerative diseases, we would love to hear from you. Our collective success is the result of unique approaches, collaboration across communities, and above all, a relentless commitment to helping people with neurodegenerative diseases.

Interested? Let’s talk.

We’d love to hear about your work and to consider the various ways in which we partner together. Submit your information in the link below and a member of our team will reach out for further discussion.

Our Pipeline

In designing our trials, we rely on the input of clinical leaders, advocacy groups, and the neurodegenerative disease community. This collaborative approach has kept people living with neurodegenerative diseases at the center of everything we do and is something we will continue in future trials. Learn more about our clinical trials and progress to date.

Wolfram syndrome is a rare, genetic, and fatal neurodegenerative disease that progressively impacts multiple organs and systems. Wolfram is considered a prototypical endoplasmic reticulum (ER) stress disorder in which ER stress and mitochondrial dysfunction are driving the underlying disease pathophysiology. The prognosis of Wolfram is poor, and many people with the disease die prematurely.

Preclinical
IND-Enabling Studies
Phase 1
Phase 2
Phase 3
Commercial

AMX0035

Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO, also known as Ursodoxicoltaurine) 

Information icon

Hover over Tap Icon Information for more information including regional details.

Progressive supranuclear palsy (PSP) is a rare, progressive, and adult-onset neurological disorder that affects walking and balance, eye movement, swallowing, and speech. People living with PSP have a life expectancy of six to eight years after initial diagnosis, and the epidemiology of PSP is similar to that of ALS. PSP is characterized by abnormal tau inclusions and is consequently also known as a tauopathy.

Learn more about our research in PSP: amylyx.com/PSP

Preclinical
IND-Enabling Studies
Phase 1
Phase 2
Phase 3
Commercial

AMX0035

Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO, also known as Ursodoxicoltaurine)

Information icon

Hover over Tap Icon Information for more information including regional details.

There is still much to learn about ALS, and R&D is a critical pillar of how we’ll deliver on our mission to one day end the suffering caused by neurodegenerative diseases.

Learn more about our commitment to research in ALS: amylyx.com/ALS

Preclinical
IND-Enabling Studies
Phase 1
Phase 2
Phase 3
Commercial

AMX0114

Antisense Oligonucleotide

Information icon

AMX0035

Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO, also known as Ursodoxicoltaurine)

Information icon

Hover over Tap Icon Information for more information including regional details.

Alzheimer’s Disease is a relentlessly progressive disease affecting the memories, thoughts and behavior of millions of people worldwide. Through our research, we aim to further characterize the biological activity of our candidates to inform potential clinical development.

Preclinical
IND-Enabling Studies
Phase 1
Phase 2
Phase 3
Commercial

AMX0035

Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO, also known as Ursodoxicoltaurine) 

Information icon

Hover over Tap Icon Information for more information including regional details.